Your session is about to expire
← Back to Search
Immunotherapy Combinations for Non-Small Cell Lung Cancer (Morpheus Lung Trial)
Morpheus Lung Trial Summary
This trial will study whether immunotherapy-based treatment combinations can help patients with metastatic NSCLC. Two groups of patients will be enrolled, depending on whether they have received systemic therapy before. Treatment will be assigned based on eligibility.
Morpheus Lung Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMorpheus Lung Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Morpheus Lung Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My blood and organs are functioning well.I have a history of certain lung conditions or signs of lung inflammation on a chest scan.I frequently need procedures to remove excess fluid from my body.I have brain metastases that are untreated or getting worse.My lung cancer is confirmed to be non-small cell type and has spread.I have at least one tumor that can be measured.My tumor can be easily reached for a biopsy.I have not received any systemic therapy for my metastatic NSCLC.I agree to either not have sex or use birth control, and not donate sperm while on treatment.My lung cancer has worsened despite treatment.My tumor shows high PD-L1 levels, with a score of 50% or more.I have had a condition where cancer spread to the lining of my brain and spinal cord.I have not had any cancer other than non-small cell lung cancer in the last 2 years.I have not had a severe infection in the last 4 weeks.You are expected to live for at least 3 more months.I am fully active or can carry out light work.I have active tuberculosis.I have or had an autoimmune disease or immune deficiency.You have had a transplant using cells or organs from another person.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Group 1: Stage 1: Cohort 2: Atezolizumab + Bevacizumab + Camonsertib
- Group 2: Stage 1: Cohort 2: Atezolizumab + Bevacizumab + Tiragolumab
- Group 3: Stage 1: Cohort 1: Atezolizumab + Cobimetinib
- Group 4: Stage 1: Cohort 1: Atezolizumab + RO6958688
- Group 5: Stage 1: Cohort 2: Docetaxel
- Group 6: Stage 1: Cohort 2: Atezolizumab + RO6958688
- Group 7: Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin
- Group 8: Stage 2: Cohort 2: Atezolizumab + RO6958688
- Group 9: Stage 2: Cohort 2: Atezolizumab + Docetaxel
- Group 10: Stage 1: Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy
- Group 11: Stage 1: Cohort 1: Atezolizumab + Tiragolumab
- Group 12: Stage 1: Cohort 1: Atezolizumab + Tiragolumab + XL092 (Zanzalintinib)
- Group 13: Stage 1: Cohort 2: Atezolizumab + Camonsertib
- Group 14: Stage 1: Cohort 2: Atezolizumab + Cobimetinib
- Group 15: Stage 1: Cohort 1: Atezolizumab
- Group 16: Stage 1: Cohort 2: Atezolizumab + Bevacizumab
- Group 17: Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin
- Group 18: Stage 1: Cohort 2: Atezolizumab + Ipatasertib
- Group 19: Stage 2: Cohort 2: Atezolizumab + Linagliptin
- Group 20: Stage 1: Cohort 2: Atezolizumab + CPI-444
- Group 21: Stage 1: Cohort 2: Atezolizumab + Evolocumab
- Group 22: Stage 1: Cohort 2: Atezolizumab + Docetaxel
- Group 23: Stage 1: Cohort 2: Atezolizumab + Sacituzumab Govitecan
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are engaged in the current clinical trial?
"This medical trial, sponsored by Hoffmann-La Roche, requires 435 participants who meet the inclusion criteria. Recruiting efforts will be centered around University Hospitals Case Medical Center, Seidman Cancer Center in Cleveland and Sarah Cannon Research Institute of Nashville."
Has there been precedent for the utilization of RO6958688 in any other research?
"Presently, 1974 trials are being conducted with RO6958688 as the focus. Out of those studies 537 have reached Phase 3 and 99928 sites globally are hosting these investigations. Notably, St Leonards in New South Wales is a major centre for this medication's research."
Can you provide an estimate of the amount of healthcare facilities presently hosting this experiment in the city?
"The trial is currently open for enrollment at University Hospitals Case Medical Center, Seidman Cancer Center in Cleveland, Ohio, Sarah Cannon Research Institute in Nashville, Tennessee and Christiana Care Health Services located in Newark Delaware. Additionally there are 4 other sites that patients can access this medication from."
Are there vacancies available in this research endeavor for participants?
"Affirmative. As per the information provided on clinicaltrials.gov, this medical study is currently in search of participants. The trial was initially published on January 2nd 2018 and was last modified November 1st 2022; 435 patients are needed from 4 distinct healthcare centres."
What applications is RO6958688 typically employed for?
"RO6958688 is frequently prescribed for lymphoma, non-Hodgkin's as well as a range of other pathologies including recurrent cervical cancer, initial treatment and metastatic bladder cancer."
Share this study with friends
Copy Link
Messenger